Eduovisual
Cardiovascular
Atrial fibrillation: cardioversion strategy and anticoagulation timing
— Most common sustained arrhythmia in adults; lifetime risk ~1 in 3 after age 55
— Responsible for ~20% of ischemic strokes; embolic strokes from AF tend to be larger and more disabling
— Paroxysmal: terminates spontaneously or with intervention within 7 days
— Persistent: continuous >7 days
— Long-standing persistent: >12 months continuous
— Permanent: shared decision to abandon rhythm control
— New staging: Stage 1 (at risk) → Stage 2 (pre-AF) → Stage 3 (AF) → Stage 4 (permanent)
— Palpitations, dyspnea, fatigue, reduced exercise tolerance, lightheadedness, syncope
— New decompensated HF, cryptogenic stroke/TIA, unexplained tachycardia in sepsis or postop
— Incidental finding on wearable, pulse check, or routine ECG
— Thyrotoxicosis, alcohol binge ("holiday heart"), pulmonary embolism, pneumonia, sepsis, post-cardiac surgery, OSA, hypokalemia/hypomagnesemia, stimulants, uncontrolled HTN
Board pearl: On Step 3, the first fork after diagnosing AF is hemodynamic stability (immediate DC cardioversion if unstable). The second fork is duration <48 h vs ≥48 h or unknown, which dictates whether you can cardiovert promptly or need 3 weeks of anticoagulation or a TEE-guided strategy.
— Highly symptomatic: palpitations, chest pressure, dyspnea, exercise intolerance, polyuria (ANP release), presyncope
— Asymptomatic ("silent AF"): discovered on routine exam, wearable alert, pre-op ECG, or after embolic event
— Atypical in elderly: fatigue, confusion, falls, worsening HF, or stroke as the first manifestation
— Onset timing: "When did palpitations start?" — critical to the <48 hour window
— If patient cannot pinpoint onset → treat as unknown duration (≥48 h)
— Prior AF episodes, prior cardioversions, prior ablation
— Prior anticoagulation, adherence, missed doses, recent interruptions for procedures
— Stroke/TIA history, bleeding history, falls, GI bleeding, intracranial hemorrhage
— HTN, HFrEF/HFpEF, CAD, valvular disease (especially mitral stenosis), cardiomyopathy
— Diabetes, obesity (BMI >27 strongly raises recurrence post-ablation), OSA
— Hyperthyroidism, CKD, prior cardiac surgery
— Alcohol use — even moderate intake is dose-dependent risk; abstinence reduces recurrence
— QT-prolonging drugs (relevant to antiarrhythmic choice)
— Sympathomimetics, decongestants, cocaine, methamphetamine, energy drinks
Step 3 management: Anchor the encounter on three questions: (1) Is the patient stable? (2) What is the AF duration? (3) What is the stroke risk (CHA₂DS₂-VASc)? These three answers determine the entire cardioversion and anticoagulation pathway and are the most-tested decision nodes.
— HR typically 110–160 in untreated AF with rapid ventricular response (RVR)
— BP: hypotension (SBP <90) → unstable
— SpO₂, RR, mental status
— Irregularly irregular pulse — hallmark; distinguishes from regular SVTs
— Variable S1 intensity (varying diastolic filling)
— Absent a-wave in JVP (no organized atrial contraction)
— Pulse deficit: apical rate > radial rate (some beats too weak to perfuse)
— Murmurs: listen for mitral stenosis (opening snap, diastolic rumble) — changes anticoagulation choice (warfarin only, not DOAC)
— Hypotension/shock: cool extremities, mottling, oliguria, altered mentation
— Acute pulmonary edema: rales, S3, hypoxia, frothy sputum
— Ongoing ischemia: ischemic chest pain with ECG changes, troponin rise driven by demand
— Pre-syncope/syncope attributable to the rhythm
— JVD, hepatomegaly, peripheral edema — suggests HF as cause or consequence
— Carotid bruits, focal neuro deficits — screen for stroke (changes anticoagulation timing)
— Goiter, tremor, lid lag, hyperreflexia → thyrotoxic AF
— Wheezing, focal crackles → pneumonia/PE precipitant
CCS pearl: Order vitals, continuous telemetry, pulse oximetry, IV access, and 12-lead ECG in the first 5 simulated minutes. If SBP <90 or chest pain with ECG ischemia, advance the clock directly to synchronized DC cardioversion with sedation (etomidate or midazolam) — do not wait for anticoagulation labs.
— Irregularly irregular RR, absent P waves, fibrillatory waves (best seen V1, II, III, aVF)
— Assess QRS width (aberrancy vs preexcitation), QT interval (antiarrhythmic safety)
— Wide, irregular, very fast (>200) AF → suspect WPW with AF — avoid AV nodal blockers (no digoxin, β-blocker, CCB, adenosine); use procainamide or DC cardioversion
— Evaluate for ischemia, prior MI (Q waves), LVH, prior infarct
— CBC, BMP (K, Mg essential before cardioversion — replete K to >4.0, Mg to >2.0)
— TSH (thyrotoxicosis), LFTs (drug dosing), coagulation panel
— Troponin if ischemia suspected; modest rise common with RVR (demand)
— BNP/NT-proBNP if HF unclear
— Pregnancy test in women of reproductive age before fluoroscopy/anticoagulation choice
— LV size and function (informs antiarrhythmic choice — no flecainide/propafenone if structural heart disease)
— LA size (>4.5 cm predicts low cardioversion success and recurrence)
— Valvular disease, especially moderate-severe mitral stenosis or mechanical valve → warfarin, not DOAC
— Pericardial effusion, RV strain (PE precipitant)
Board pearl: The single most commonly missed pre-cardioversion check is electrolytes. Cardioverting with K <3.5 risks post-shock VT/VF. Always replete K and Mg before elective cardioversion, even if the rhythm appears stable.
— Indications:
— AF duration ≥48 h or unknown, and patient/clinician wants cardioversion without waiting 3 weeks on anticoagulation
— Hemodynamically stable but rhythm control desired sooner
— Recurrent AF in patient with anticoagulation interruption
— Looks for thrombus in left atrial appendage (LAA) and "smoke" (spontaneous echo contrast)
— TEE-negative + start anticoagulation immediately → can proceed to cardioversion; continue anticoagulation ≥4 weeks post-cardioversion regardless of CHA₂DS₂-VASc
— TEE-positive (LAA thrombus) → defer cardioversion, anticoagulate ≥3–6 weeks, repeat TEE before another attempt
— 24–48 h Holter: symptomatic, frequent episodes
— 14–30 day patch (Zio): infrequent symptoms
— Implantable loop recorder: cryptogenic stroke workup or rare events
— CHF, HTN, Age ≥75 (2), DM, Stroke/TIA (2), Vascular disease, Age 65–74, Sex (female)
— Anticoagulate: men ≥2, women ≥3; consider: men =1, women =2
Key distinction: TEE replaces the "3 weeks of anticoagulation before cardioversion" rule only if the patient is started on anticoagulation at the time of TEE and continues for ≥4 weeks after. TEE alone, without anticoagulation, does not protect against post-cardioversion stroke.
— Unstable (hypotension, ischemic chest pain, acute HF, altered mentation): immediate synchronized DC cardioversion regardless of AF duration or anticoagulation status
— Start anticoagulation as soon as feasible after cardioversion (heparin bridge, then continue ≥4 weeks; long-term per CHA₂DS₂-VASc)
— Stable: proceed to duration assessment
— <48 hours and clearly known: may cardiovert without TEE
— Still start anticoagulation peri-cardioversion; continue ≥4 weeks
— Higher-risk patients (CHA₂DS₂-VASc ≥2) — many cardiologists prefer TEE even <48 h
— ≥48 hours or unknown: two acceptable strategies:
— (a) Delayed approach: therapeutic anticoagulation ≥3 weeks → cardiovert → continue ≥4 weeks
— (b) Early approach (TEE-guided): start anticoagulation → TEE → if no thrombus, cardiovert same day → continue ≥4 weeks
— EAST-AFNET 4 and recent guidelines favor early rhythm control within 1 year of diagnosis, especially symptomatic patients or HFrEF
— Rate control acceptable for asymptomatic, elderly, long-standing persistent AF
— Decision is independent of anticoagulation: rhythm control success does NOT remove anticoagulation indication
Step 3 management: Memorize the "3 + 4 rule": 3 weeks of therapeutic anticoagulation before cardioversion (if ≥48 h), 4 weeks after cardioversion (always). Then reassess long-term anticoagulation by CHA₂DS₂-VASc. The "before" can be bypassed with TEE; the "after" cannot.
— β-blockers: metoprolol IV 5 mg q5min ×3, then PO; preferred if CAD, HFrEF (use carvedilol/metoprolol succinate)
— Non-dihydropyridine CCBs: diltiazem IV bolus 0.25 mg/kg then drip; avoid in HFrEF (negative inotropy)
— Digoxin: adjunct, especially HFrEF or hypotension intolerant of β-blocker/CCB; slow onset
— Amiodarone: rate control in critically ill; also rhythm conversion — but counts as cardioversion (anticoagulation rules apply)
— Flecainide or propafenone: structurally normal heart only; "pill-in-pocket" for select paroxysmal AF — always co-administer AV nodal blocker (prevents 1:1 atrial flutter conduction)
— Ibutilide: IV, monitor QT 4 hours post-dose; risk of torsades
— Amiodarone: safe in structural heart disease and HF; slower onset
— Dofetilide: inpatient initiation, QT monitoring × 3 days
— DOACs preferred for nonvalvular AF: apixaban 5 mg BID (2.5 BID if 2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5); rivaroxaban 20 mg with dinner; dabigatran 150 mg BID; edoxaban 60 mg daily
— Warfarin (INR 2–3) required for moderate-severe mitral stenosis and mechanical prosthetic valves
— Parenteral bridge (LMWH or UFH) used peri-cardioversion when starting warfarin; not needed when starting a DOAC
— DOAC at least 3 weeks prior with documented adherence, or warfarin INR ≥2 weekly × 3 weeks
— Continue ≥4 weeks post; long-term per CHA₂DS₂-VASc
Board pearl: "Pill-in-pocket" flecainide/propafenone is only appropriate for infrequent paroxysmal AF, structurally normal heart, and a prior successful in-hospital trial. Always paired with a β-blocker or CCB taken 30 minutes before to prevent rapid 1:1 conduction if AF organizes into flutter.
— Conscious sedation (etomidate, midazolam + fentanyl, or propofol with anesthesia)
— Biphasic shock: start 150–200 J anterior-posterior pad placement preferred (higher success than anterolateral)
— Synchronize to R wave (avoid R-on-T → VF); escalate energy if unsuccessful
— Pre-treatment with ibutilide or amiodarone increases conversion success in resistant AF
— Pre-procedure: confirm K >4.0, Mg >2.0, NPO status, anticoagulation status, consent
— Telemetry observation 2–4 h
— Continue anticoagulation ≥4 weeks minimum, regardless of CHA₂DS₂-VASc or stroke risk
— Reassess CHA₂DS₂-VASc for indefinite anticoagulation
— Counsel: ~50% recurrence within 1 year without antiarrhythmic therapy
— Class I indication: symptomatic paroxysmal AF refractory or intolerant to ≥1 antiarrhythmic
— Class I: HFrEF with AF (CASTLE-AF showed mortality benefit)
— Reasonable as first-line in symptomatic paroxysmal AF (EARLY-AF, STOP-AF)
— Continue anticoagulation ≥3 months post-ablation; long-term decision by CHA₂DS₂-VASc, not by perceived ablation success
— For patients with long-term anticoagulation indication but contraindication to anticoagulation (recurrent GI bleed, prior ICH, falls)
— Requires short-term post-implant anticoagulation/antiplatelet bridge
CCS pearl: After successful cardioversion in the simulated case, do NOT discontinue anticoagulation at discharge "because the patient is now in sinus." Order anticoagulation continuation for 4 weeks minimum and a follow-up clinic visit in 2–4 weeks for reassessment — this is the most commonly missed CCS order.
— Higher stroke risk (age ≥75 = 2 points CHA₂DS₂-VASc) and higher bleed risk — net benefit still favors anticoagulation
— Apixaban is the DOAC of choice in frailty (ARISTOTLE: fewer major bleeds vs warfarin, including in ≥80)
— Falls alone are NOT a contraindication — modeled risk: would need ~295 falls/year for fall-related bleed risk to outweigh stroke benefit
— Lenient rate control (HR <110) often appropriate (RACE II)
— Avoid flecainide/propafenone (often have structural disease, CAD)
— Consider LAA occlusion if recurrent falls with ICH or major bleeding
— Apixaban: 2.5 mg BID if any 2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5 mg/dL; usable down to CrCl 15 and in HD (FDA label)
— Rivaroxaban: 15 mg daily if CrCl 15–50; avoid <15
— Dabigatran: 75 mg BID if CrCl 15–30; avoid <15 and on HD (highly renally cleared)
— Edoxaban: avoid if CrCl >95 (less effective) or <15
— Warfarin: preferred at CrCl <15 historically; apixaban now reasonable per recent data
— Child-Pugh C: avoid all DOACs
— Child-Pugh B: avoid rivaroxaban; apixaban/edoxaban use with caution
— Warfarin used with careful INR monitoring (altered synthesis of clotting factors complicates)
— Dofetilide and sotalol: renally cleared, QT-prolonging — inpatient initiation, dose by CrCl
— Amiodarone: hepatic metabolism, no renal adjustment; monitor LFTs, TSH, PFTs
Key distinction: Apixaban is uniquely flexible across the renal spectrum (15 → HD) and has the best bleeding profile in elderly — it is the most testable answer for "elderly patient with AF and CKD stage 4." Dabigatran is the worst choice in advanced CKD.
— AF rare in pregnancy; suspect structural heart disease, peripartum cardiomyopathy, thyroid storm, or congenital lesion
— Rate control: metoprolol or propranolol (avoid atenolol — IUGR); digoxin safe
— Cardioversion safe in pregnancy if unstable; fetal monitoring during procedure
— Anticoagulation:
— DOACs and warfarin contraindicated (warfarin teratogenic 6–12 wk; bleeding risk near delivery)
— Use LMWH throughout, switch to UFH near delivery
— Mechanical valve in pregnancy: complex regimen with warfarin in 2nd trimester at low doses or LMWH with anti-Xa monitoring
— Endurance athletes have 2–5× AF risk
— Detraining and reduced training intensity reduces recurrence
— Ablation often preferred over chronic antiarrhythmics (preserves performance)
— Treat thyrotoxicosis first; AF often reverts to sinus with euthyroidism
— Higher embolic risk during thyrotoxic state — anticoagulate per CHA₂DS₂-VASc (some experts anticoagulate all thyrotoxic AF until euthyroid)
— Avoid amiodarone (worsens thyroid disease)
— Often transient; β-blocker prophylaxis reduces incidence
— Long-term stroke risk approaches non-surgical AF — anticoagulate per CHA₂DS₂-VASc beyond 30 days if AF recurs or persists
— Cardioversion same rules (<48 h vs ≥48 h, anticoagulation timing)
Board pearl: Postoperative AF after CABG is not benign — long-term stroke risk is elevated and current guidelines recommend treating POAF lasting >48 h with the same anticoagulation framework as non-surgical AF. Don't dismiss it as "just postop."
— 5-fold increase vs age-matched controls; ~20% of all ischemic strokes
— LAA is source in ~90% of nonvalvular AF thrombi
— Strokes are larger, more disabling, higher mortality than non-cardioembolic
— Peri-cardioversion risk: 1–2% without anticoagulation if AF ≥48 h
— Tachycardia-induced cardiomyopathy: persistent HR >100 → reversible LV dysfunction; rate or rhythm control restores function over weeks-months
— Loss of atrial kick exacerbates HFpEF symptoms more than HFrEF
— Major bleed ~2–3%/yr on DOAC, slightly higher on warfarin
— ICH: 50% lower with DOACs vs warfarin
— GI bleed: rivaroxaban and dabigatran > warfarin > apixaban
— Reversal agents: idarucizumab for dabigatran; andexanet alfa for apixaban/rivaroxaban; 4-factor PCC if andexanet unavailable; vitamin K + PCC for warfarin
— Class IC (flecainide, propafenone): VT in structural heart disease, 1:1 flutter conduction
— Class III (sotalol, dofetilide, ibutilide): torsades de pointes from QT prolongation
— Amiodarone toxicities: pulmonary fibrosis, hepatitis, thyroid (hyper or hypo), corneal deposits, blue-gray skin, neuropathy
— Especially in tachy-brady (sick sinus) syndrome — may need pacemaker
Step 3 management: For life-threatening DOAC-associated bleed: hold drug, supportive care (transfuse, mechanical compression), activated charcoal if last dose <2–4 h, give specific reversal agent, and consider hemodialysis only for dabigatran (others are highly protein-bound).
— Hemodynamic instability: SBP <90, signs of shock → emergent synchronized DC cardioversion
— Acute pulmonary edema with RVR refractory to rate control
— AF with WPW (wide, irregular, fast) → procainamide or DCCV; cardiology and EP consult
— Stroke or TIA presentation → stroke team, neuroimaging, decide on thrombolysis/thrombectomy before anticoagulation
— Major bleeding on anticoagulation
— New AF with HF decompensation, ischemia, or syncope
— Inpatient antiarrhythmic initiation: dofetilide and sotalol require 3-day inpatient monitoring with QT and renal function
— Failed outpatient rate control
— Cardioversion with sedation in patients with significant comorbidities
— Stable AF with controlled rate, no ischemia, no HF, anticoagulation feasible
— Known paroxysmal AF, self-terminated, on chronic therapy
— Cardiology/EP: recurrent symptomatic AF, antiarrhythmic selection, ablation candidacy, WPW
— Stroke neurology: AF presenting with TIA/stroke for anticoagulation timing
— Hematology: anticoagulation in pregnancy, antiphospholipid syndrome, recurrent bleed
— Cardiothoracic surgery: Cox-Maze with concomitant cardiac surgery; LAA exclusion
— TIA: start ~1 day
— Small stroke: ~3 days
— Moderate stroke: ~6 days
— Large stroke or hemorrhagic transformation: ~12 days (or longer)
— Earlier initiation (ELAN trial) is increasingly supported but individualize
CCS pearl: When the simulated AF patient is "stable but symptomatic with HR 145," advance the clock by ordering IV diltiazem or metoprolol, recheck vitals in 15 minutes, transition to PO once controlled, and only then turn to the anticoagulation/cardioversion fork. Skipping rate control while debating rhythm is a common CCS error.
— Sawtooth flutter waves (best in II, III, aVF), typical atrial rate 250–350, ventricular response often regular at 150 (2:1) or variable
— Same anticoagulation rules as AF (CHA₂DS₂-VASc, peri-cardioversion 3+4 weeks)
— More amenable to cure by cavotricuspid isthmus ablation (>95% success for typical flutter)
— ≥3 distinct P-wave morphologies, irregularly irregular — mimics AF
— Associated with severe COPD, hypoxia, hypomagnesemia
— Treat underlying disease; avoid β-blockers (bronchospasm), use verapamil or magnesium
— Does NOT carry AF stroke risk; no anticoagulation indication based on rhythm alone
— Regular, narrow-complex, abrupt onset/offset
— Vagal maneuvers, adenosine; no chronic anticoagulation
— Regular, P-wave morphology different from sinus; may be focal or reentrant
— Can mimic irregular rhythm; P waves preserved
— Wide, irregular, often >200 bpm — "FBI" pattern (fast, broad, irregular)
— Avoid AV nodal blockers (β-blockers, CCBs, digoxin, adenosine) — can precipitate VF
— Use procainamide or ibutilide, or DC cardioversion
Key distinction: Irregularly irregular ≠ always AF. MAT has discrete varied P waves and demands COPD/hypoxia management, not anticoagulation. WPW with AF demands avoidance of the very drugs (β-blocker, CCB, digoxin) you would normally reach for in AF — high-yield trap.
— PVCs: wide complexes interrupting sinus rhythm; "skipped beats" sensation; benign if structurally normal heart
— Sustained VT: wide complex tachycardia, usually regular — distinguish from AF with aberrancy by AV dissociation, capture/fusion beats, concordance
— Alternating bradycardia and AF; pacemaker often needed before/with antiarrhythmics
— Hyperthyroidism: tremor, weight loss, heat intolerance; can also cause AF
— Pheochromocytoma: episodic HTN, headache, diaphoresis, palpitations
— Panic disorder: regular sinus tachycardia, normal ECG; diagnosis of exclusion
— Hypoglycemia: catecholamine surge
— Anemia, dehydration, sepsis: compensatory sinus tachycardia
— Pulmonary embolism: sinus tachy, occasionally AF; check D-dimer/CT-PA if risk factors
— Stimulants: caffeine, decongestants, cocaine, methamphetamine, β-agonist inhalers
— Levothyroxine excess, theophylline, tricyclics, antipsychotics (QT effects)
Board pearl: A patient with palpitations and an irregular pulse who turns out to have regular sinus rhythm with PACs/PVCs on ECG does not need anticoagulation. The diagnosis of AF requires actual ECG documentation — never anticoagulate on symptoms alone.
— Men ≥2, women ≥3 → recommended
— Men =1, women =2 → consider, shared decision
— Apixaban 5 mg BID typical default; warfarin if mechanical valve or moderate-severe MS
— Reassess annually: renal function, weight, age thresholds, bleeding events, falls
— If maintained on rhythm control: select antiarrhythmic by structural status
— Normal heart: flecainide, propafenone, dronedarone, sotalol
— CAD/structural: dofetilide, sotalol, amiodarone
— HFrEF: amiodarone, dofetilide
— Rate control alone if rhythm not pursued: β-blocker or non-DHP CCB
— Weight loss: ≥10% body weight reduces AF burden and recurrence (LEGACY trial)
— BP control <130/80
— Glycemic control: A1c <7
— Alcohol: reduce or abstain (≤1 drink/day; abstinence preferred — ALCOHOL-AF trial)
— OSA: CPAP if AHI elevated
— Exercise: moderate aerobic, avoid extreme endurance volumes
— Smoking cessation, caffeine moderation
— Symptom diary, pulse self-checks, smartphone/wearable ECG
— When to seek care: stroke symptoms (FAST), syncope, sustained HR >120 with symptoms
— Anticoagulation: never miss doses, no NSAIDs, alert all providers/dentists before procedures
Step 3 management: Do not "stop anticoagulation now that the patient is in sinus rhythm" — long-term anticoagulation in AF is determined by CHA₂DS₂-VASc, not current rhythm. Even with successful ablation, anticoagulation continues per stroke risk for at least 2 months and likely indefinitely if score is high.
— Clinic visit at 2–4 weeks: assess rhythm (ECG), symptoms, anticoagulation adherence, side effects
— Decision at 4 weeks: stop anticoagulation only if CHA₂DS₂-VASc 0 (men) or 1 (women) AND sustained sinus
— Ambulatory monitoring (14-day patch) at 3–6 months if rhythm strategy chosen
— Warfarin: INR weekly until stable, then every 2–4 weeks; goal 2–3
— DOACs: no routine level monitoring; check annually — CBC, renal function (CrCl), LFTs, adherence; more often if CrCl <60 or age >75
— Weight check (apixaban dose adjustment threshold 60 kg)
— Screen for bleeding: stool occult blood, hemoglobin trend, bruising
— Amiodarone: TSH and LFTs every 6 months; PFTs and CXR baseline and annually or with symptoms; ophthalmology if visual symptoms
— Dofetilide/sotalol: ECG (QTc) and renal function every 3–6 months
— Flecainide/propafenone: ECG to ensure no QRS widening; stress test if CAD risk emerges
— Resting HR <110 (lenient) or <80 (strict if symptomatic)
— Holter or exercise test if symptoms persist
— Stroke and bleeding risks discussed in absolute terms (e.g., "5% per year stroke without, 1.5% per year bleed with")
— Fall risk: usually does not contraindicate anticoagulation
— Pregnancy planning: switch off DOAC/warfarin to LMWH
— Driving: most jurisdictions permit driving after asymptomatic AF; commercial drivers/pilots have stricter rules
CCS pearl: On every Step 3 AF case, order a follow-up appointment 2–4 weeks post-discharge and label specific monitoring labs (CBC, BMP, INR or annual DOAC labs). Failing to schedule follow-up is a common scoring miss in longitudinal cases.
— Discuss: stroke risk during procedure (1–2% without anticoagulation), need for sedation, recurrence risk (~50% at 1 year), alternatives (rate control, ablation)
— In emergent unstable AF, implied consent applies — proceed with DC cardioversion without delay; document indication and inability to obtain consent
— Explicit discussion required: absolute stroke risk reduction, absolute bleed risk increase, patient values (fall risk, lifestyle, prior bleeding events)
— Document the conversation, especially when declining anticoagulation against guideline recommendation
— Patient with dementia and recurrent falls refusing anticoagulation: assess capacity for this specific decision; involve surrogate if lacking
— Capacity is decision-specific and can fluctuate
— Discharge from ED/hospital is the most dangerous moment for AF patients
— Confirm: anticoagulation prescription filled, patient understands the 3+4 rule, follow-up scheduled, contact number for bleeding/stroke symptoms
— Reconcile medications: NSAIDs, antiplatelets, drug-drug interactions with DOACs (CYP3A4/P-gp inhibitors — amiodarone, diltiazem, dronedarone, antifungals)
— Commercial drivers and pilots: report syncope or symptomatic arrhythmia per FAA/DOT regulations
— Documenting AF in patients with public-safety occupations triggers fitness-for-duty review
— Look-alike/sound-alike: apixaban dosing (5 vs 2.5) is a common error; double-check dose-reduction criteria
— Warfarin INR communication: closed-loop with anticoagulation clinic
— In advanced age or limited life expectancy, discuss whether aggressive rhythm control or anticoagulation aligns with goals
Board pearl: A patient who refuses anticoagulation after capacity-confirmed, fully informed discussion has the right to do so. Document the conversation, offer alternatives (LAA occlusion), and continue to revisit the decision over time — autonomy outweighs beneficence in capacitated patients.
Key distinction: "Valvular AF" in 2024 guidelines means moderate-to-severe mitral stenosis or mechanical prosthetic valve only — NOT all valvular disease. Bioprosthetic valves, AS, MR, and TR are all eligible for DOACs.
Step 3 management: When a stem gives you AF + a specific time window, the first question is always the 48-hour clock. If the stem says "started this morning," that is the giveaway you can cardiovert sooner. If it says "found incidentally," treat as ≥48 h.
In atrial fibrillation, the cardioversion-anticoagulation strategy is governed by hemodynamic stability first, AF duration second (the 48-hour threshold), and long-term stroke risk by CHA₂DS₂-VASc third — apply the "3 weeks before, 4 weeks after" anticoagulation rule for any AF ≥48 hours, with TEE as an accepted shortcut that replaces only the "before."
Board pearl: If you remember only one rule for Step 3 AF questions, make it the "3 + 4" — 3 weeks of therapeutic anticoagulation before elective cardioversion when AF has been present ≥48 hours, and 4 weeks after every cardioversion, then reassess long-term anticoagulation by CHA₂DS₂-VASc. This single framework answers the majority of AF management vignettes.